MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a leader in antibody optimization, has selected two humanized monoclonal antibody candidates, XmAb™ 5574 and XmAb™ 5483, for IND-enabling pre-clinical development for the treatment of B-cell malignancies and autoimmune diseases. XmAb 5574 and XmAb 5483 target the antigens CD19 and CD40, respectively. CD19 is a validated target for B-cell cancers and inflammatory diseases. CD40 is a validated target for B-cell cancers and a variety of solid tumor cancers including bladder, renal and ovarian cancer. Xencor has started pre-clinical studies that will allow the Company to file Investigational New Drug (IND) applications with the U.S. Food and Drug Administration for these candidates.
